| Identification | Back Directory | [Name]
3H-Pyrazol-3-one, 2-(3,4-diMethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-Methyl- | [CAS]
376592-42-6 | [Synonyms]
SB559448
SB-559448
SB 559448
TotroMbopag
KWJKFQSAMABKBG-CYYJNZCTSA-N
3H-Pyrazol-3-one, 2-(3,4-diMethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-Methyl- | [Molecular Formula]
C25H22N8O2 | [MDL Number]
MFCD19443699 | [MOL File]
376592-42-6.mol | [Molecular Weight]
466.49 |
| Hazard Information | Back Directory | [Uses]
Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology[1]. | [References]
[1] Alper P B, et al. Discovery and biological evaluation of benzo [a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor[J]. Bioorganic & medicinal chemistry letters, 2008, 18(19): 5255-5258. DOI:10.1016/j.bmcl.2008.08.068 |
|
|